Equities research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a research report issued on Tuesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Several other research analysts have also recently weighed in on AKTX. Alliance Global Partners started coverage on Akari Therapeutics in a research note on Tuesday, November 1st. They set a “buy” rating and a $4.00 target price for the company. HC Wainwright assumed coverage on Akari Therapeutics in a report on Monday, December 5th. They set a “buy” rating and a $1.50 target price for the company.
Akari Therapeutics Stock Down 1.8 %
Shares of AKTX stock opened at $0.49 on Tuesday. The stock has a 50-day simple moving average of $0.52 and a 200 day simple moving average of $0.74. Akari Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $1.61. The stock has a market capitalization of $36.54 million, a P/E ratio of -1.40 and a beta of 1.32.
Institutional Investors Weigh In On Akari Therapeutics
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid.
- Get a free copy of the StockNews.com research report on Akari Therapeutics (AKTX)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.